AIM ImmunoTech Inc.
AIM- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000946644
In the last 90 days, AIM ImmunoTech Inc. insiders filed 4 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $325.6K in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding AIM ImmunoTech Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 34 | 38 | +4 |
| Shares | 4.49M | 4.33M | −162.4K (−3.6%) |
| Value | $3.01M | $1.97M | −$1.04M (−34.6%) |
New holders (6)
Institutions that held AIM ImmunoTech Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 29,061 | $13.0K | 0.00% |
| HRT Financial LP | 10,816 | $4.00K | 0.00% |
| VisionPoint Advisory Group, LLC | 3,142 | $1.43K | 0.00% |
| AdvisorNet Financial, Inc | 500 | $228 | 0.00% |
| IAG Wealth Partners, LLC | 480 | $218 | 0.00% |
| Qube Research & Technologies Ltd | 2 | $1 | 0.00% |
Sold out (2)
Institutions that held AIM ImmunoTech Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Susquehanna International Group, LLP | 54,613 | $36.6K |
| Proequities, Inc. | 500 | $335 |